Engineering Diagnostic and Therapeutic Gut Bacteria

Brian P Landry,Jeffrey J Tabor,Brian P. Landry,Jeffrey J. Tabor
DOI: https://doi.org/10.1128/microbiolspec.bad-0020-2017
IF: 3.7
2017-09-22
Microbiology Spectrum
Abstract:ABSTRACT Genetically engineered bacteria have the potential to diagnose and treat a wide range of diseases linked to the gastrointestinal tract, or gut. Such engineered microbes will be less expensive and invasive than current diagnostics and more effective and safe than current therapeutics. Recent advances in synthetic biology have dramatically improved the reliability with which bacteria can be engineered with the sensors, genetic circuits, and output (actuator) genes necessary for diagnostic and therapeutic functions. However, to deploy such bacteria in vivo , researchers must identify appropriate gut-adapted strains and consider performance metrics such as sensor detection thresholds, circuit computation speed, growth rate effects, and the evolutionary stability of engineered genetic systems. Other recent reviews have focused on engineering bacteria to target cancer or genetically modifying the endogenous gut microbiota in situ . Here, we develop a standard approach for engineering “smart probiotics,” which both diagnose and treat disease, as well as “diagnostic gut bacteria” and “drug factory probiotics,” which perform only the former and latter function, respectively. We focus on the use of cutting-edge synthetic biology tools, gut-specific design considerations, and current and future engineering challenges.
microbiology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to develop a standard method for designing "smart probiotics" which can simultaneously diagnose and treat diseases related to the gastrointestinal tract (gut). In addition, the paper also explores how to design "diagnostic gut bacteria" with only diagnostic functions and "drug factory probiotics" with only treatment functions. Specifically, the paper focuses on the following aspects: 1. **Design of Genetically Engineered Bacteria**: The paper discusses how to use the latest synthetic biology tools to design these bacteria in order to improve their performance in vivo. This includes factors such as selecting suitable gut - adapted strains, considering sensor detection thresholds, circuit calculation speed, the influence of growth rate, and the evolutionary stability of the engineered genetic system. 2. **Diagnostic and Treatment Functions**: - **Smart Probiotics**: These bacteria can sense one or more gut biomarkers, calculate whether these biomarkers indicate a disease, and respond by delivering a precise dose of one or more appropriate therapies. - **Diagnostic Gut Bacteria**: These bacteria can sense one or more biomarkers, calculate whether these biomarkers indicate a disease, and produce a reporter molecule that can be externally measured by a doctor. - **Drug Factory Probiotics**: These bacteria can continuously produce a therapeutic substance in vivo. 3. **Existing Challenges**: The paper also discusses the current and future challenges in designing these engineered bacteria, including how to ensure the stability and effectiveness of these bacteria in the complex and variable gut environment. 4. **Specific Case Studies**: The paper mentions some specific case studies, such as using *Lactococcus lactis* to produce the anti - inflammatory cytokine IL - 10 to treat colitis, and using *Escherichia coli* to sense thiosulfate as a new biomarker for colitis. In summary, this paper aims to develop more effective and safer methods for diagnosing and treating gut diseases through synthetic biology methods.